GOOD NEWS FOR SUFFERERS OF CHRONIC AIRWAY DISEASE

Published Aug 6, 2014
Auckland, New Zealand - Chronic obstructive pulmonary disease (COPD), resulting usually from long term tobacco smoking and/or severe air pollution, is a major health issue in most countries, and is increasing as the population ages. Daily use of equipment that warms and humidifies inspired air improves breathing and quality of life and reduces exacerbations of moderate to severe COPD and bronchiectasis. Researchers from the University of Auckland in New Zealand set out to establish whether daily use of equipment that warms and humidifies inspired air provides good value for money for patients with moderate or severe airways disease. In a 12-month randomised controlled trial of humidification of inspired air at home, direct medical costs, including those of hospital admissions, Emergency Department and general practitioner consultations, were comparable or lower in the patients with the intervention than in a control group with usual clinical care. With the intervention costing $NZ2059 ($US1700) annually, the mean cost per unit of health benefit (quality adjusted life year or ‘QALY’) was well within the range of fundability for new medicines and devices in New Zealand. “Long-term humidification therapy improves quality of life and it is likely to be cost effective for patients with moderate to severe airways disease in most developed countries,” said Dr. Richard Milne, PhD, Managing Director, Health Outcomes Associates, Ltd in Auckland, and lead investigator on the study. The full study, “Long-Term Air Humidification Therapy Is Cost-Effective for Patients with Moderate or Severe Chronic Obstructive Pulmonary Disease or Bronchiectasis,” is published in Value in Health. Is humidification of inspired air cost effective for patients with severe airway disease?

Related Stories

Rethinking Medication Adherence: A Stakeholder Blueprint

May 12, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a report from its Medication Adherence and Persistence Special Interest Group that provides valuable insights into the perspectives of key stakeholders on interventions to improve medication adherence. The report, “Stakeholders’ Perspectives on Medication Adherence Enhancing Interventions: An ISPOR Report,” was published in the May 2025 issue of Value in Health.

New Research Reveals Surprising Trends in Women's Health Economics Authorship

May 12, 2025

Value in Health, the official journal of ISPOR announced the publication of new research analyzing women's representation in authorship of papers submitted to and published in Value in Health. The report, “How Well Are Women Represented in Authorship in HEOR? An Analysis of Value in Health: An ISPOR Report,” was published in the May 2025 issue of Value in Health.

ISPOR Publishes Insights From Its First Global HTA Roundtable

Apr 21, 2025

ISPOR—The Professional Society for Health Economics and Outcomes Research (HEOR) published the insights from its first Global Health Technology Assessment (HTA) Roundtable in an article in the March/April issue of Value & Outcomes Spotlight.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×